DISEASE CHARACTERISTICS:

Newly diagnosed acute lymphoblastic leukemia (ALL)

B-precursor or T-precursor ALL

No Burkitt type leukemia (FAB L3; SIg positive; t(8;14) or variant)

No known Ph+ ALL at time of diagnosis

Enrollment on CALGB-C10001 (or its successor trial) for CALGB patients with Philadelphia-positive ALL take priority over enrollment on this protocol

Patients enrolled on this study but are later found to meet the following criteria for Ph+ ALL eligibility criteria for protocol CALGB-C10001 (or its successor trial) are removed from this study and enrolled on CALGB-C10001 (or its successor study):



BCR-ABL fusion transcript determined by FISH or RT-PCR

t(9;22)(q34;q11) or variant determined by cytogenetics

All CALGB patients are required to participate in CALGB-8461

All SWOG patients are required to participate in SWOG-9007

PATIENT CHARACTERISTICS:



ECOG performance status 0-2

No Down syndrome

PRIOR CONCURRENT THERAPY:



No prior therapy for acute leukemia except emergency therapy (i.e., corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys

Single-dose intrathecal cytarabine is allowed prior to registration for patient convenience provided systemic chemotherapy begins within 72 hours of intrathecal therapy

Prior steroid therapy allowed

DISEASE CHARACTERISTICS:

Morphologically confirmed diagnosis of acute myeloid leukemia (AML)
Must have received = 1 prior chemotherapy regimen for AML

Any type of prior chemotherapy allowed
Must have achieved a complete remission that lasted = 3 months after the last induction regimen and then subsequently relapsed

Relapse must be documented by a bone marrow examination demonstrating > 5% blasts in the bone marrow not attributable to another cause
No acute promyelocytic leukemia (i.e., APL, FAB M3) or blastic transformation of chronic myelogenous leukemia
No clinical evidence of leptomeningeal disease
Concurrent registration on research study SWOG-9007 required
PATIENT CHARACTERISTICS:

Zubrod performance status 0-2
Serum creatinine = 2.0 times upper limit of normal (ULN)
Total bilirubin = 2.0 times ULN (unless elevation is primarily due to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis AND not due to liver dysfunction)
AST and ALT = 3.0 times ULN
Ejection fraction = 45% by echocardiogram or MUGA scan
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias
No HIV positivity unless the following criteria are met:

No history of AIDS-defining events
CD4 count = 500/mm³
Viral load < 25,000 copies (< 50 copies if on combination antiretroviral therapy)
Not receiving zidovudine or stavudine as part of combination antiretroviral therapy
No uncontrolled systemic fungal, bacterial, viral, or other infection, defined as exhibiting ongoing signs/symptoms related to the infection with no improvement despite appropriate antibiotics or other treatment
Other prior malignancy allowed provided patient is in remission from that malignancy
PRIOR CONCURRENT THERAPY:

See Disease Characteristics
At least 6 months since prior chemotherapy or radiotherapy and recovered
No prior autologous or allogeneic stem cell transplantation
Prior or concurrent hydroxyurea to control high WBC counts allowed
No concurrent statin treatments

**Open To All Components**

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:

Biopsy proven small lymphocytic lymphoma (SLL)
Chronic lymphocytic leukemia (CLL)* as evidenced by the following criteria:

Peripheral blood lymphocyte count > 5,000/mm³ consisting of small to moderate size lymphocytes
Immunophenotyping consistent with CLL, defined by the following:

The predominant population of lymphocytes share both B-cell antigens (CD19, CD20, or CD23) as well as CD-5 in the absence of other pan-T-cell markers (CD-3 or CD-2)
Dim surface immunoglobulin expression
Exclusively kappa and lambda light chains
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy samples NOTE: *Splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL
Has e 1 of the following indications** for chemotherapy:

Evidence of progressive marrow failure as manifested by the development of or worsening anemia (hemoglobin d 11 g/dL) and/or thrombocytopenia (platelet count d 100,000/mm³)
Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly
Has e 1 of the following disease-related symptoms:

Weight loss > 10% within the past 6 months
Extreme fatigue attributed to CLL
Fevers > 100.5^oF for 2 weeks without evidence of infection
Night sweats without evidence of infection
Progressive lymphocytosis (not due to the effects of corticosteroids) with an increase of > 50% over a 2-month period or an anticipated doubling time of < 6 months NOTE: **Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease are not sufficient indications for study treatment
PATIENT CHARACTERISTICS:

ECOG performance status 0-3
Life expectancy e 12 months
Total bilirubin d 3.0 times upper limit of normal (ULN) (unless due to Gilbert's disease)

Direct bilirubin < 1.5 mg/dL (in patients with Gilbert's disease)
SGOT d 3.0 times ULN (unless due to hepatic involvement by CLL)
Creatinine d 1.5 times ULN
Urine protein:creatinine ratio < 1.0 OR < 1 g of protein by 24-hour urine collection
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 12 months after completion of study treatment
Willing to provide mandatory blood and tissue samples
None of the following cardiovascular conditions:

NYHA class III-IV heart disease
Myocardial infarction within the past 6 months
Unstable angina
Stroke, cerebrovascular accident, or transient ischemic attack within the past 6 months
Arterial thromboembolic events within the past 12 months
Clinically significant peripheral vascular disease
Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 100 mm Hg

Hypertension allowed provided it is controlled with a stable anti-hypertensive regimen
History of hypertensive crises or hypertensive encephalopathy
Deep venous thromboses or pulmonary embolism within the past 12 months
No evidence of bleeding diathesis or coagulopathy
No uncontrolled or active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment
No active or recent history (within the past 30 days) of hemoptysis (e ½ teaspoon of bright red blood per episode)
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
No active peptic ulcer disease
No serious non-healing wound, ulcer, or bone fracture
No significant traumatic injury within the past 28 days
No uncontrolled infection
No active HIV infection
No other active primary malignancy (except nonmelanoma skin cancer or carcinoma in situ of the cervix) requiring treatment or limiting survival to d 2 years
No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude study participation
PRIOR CONCURRENT THERAPY:

Prior corticosteroids allowed
More than 4 weeks since prior radiotherapy
More than 28 days since prior and no

**Study has lost funding. No CREDIT. No longer required for main study eligibility.**

1. Pts. must be registered on one of the following SWOG treatment protocols: 8326, 8600, 8612, 9034, 9108 and all new leukemia protocols approved as of 1990.
2. ECOG pts. must be registered to SWOG 9300.

**Study has lost funding. No CREDIT. No longer required for main study eligibility.**
1. Pts. must be registered on a SWOG treatment study for ALL, CLL, AML, or CML or MDS.

1. Must have a dx of B-CLL, meeting criteria listed in 3.1.1.1,3.1.1.2,3.1.1.3
2. Pts. must require chemo, the last admin. of chemo. must have been completed 6 weeks or greater prior to study tx. Must meet indications for chemo. listed in section 3.1.2.1, 3.1.2.2,3.1.2.3, 3.1.2.4,3.1.2.5Pts.
3. Pts. must have either: demonstrated progression after at least one cycle of either an alkylating agent-based or purine nucleoside based regimen, or failed to achieve a meaningful response, or relapsed after prior therapy.
4. Prior therapy with Rituximab is OK, at least 8 weeks should have elapsed between the last Rituximab dose and reg.
5. No previous PCR therapy or CAMPATH-1H therapy prior to entering study.
6. No active infection requiring antibiotic.
7. Pts. whose bone marrow function is attributable to dysplasia related to prior therapy are not eligible.
8. Pts. must be tested for Hep B virus infection.